ライフサイエンスコーパス: clinical testing

1 arly-phase trials only to fail in late-stage clinical testing.

2 new tuberculosis vaccine candidates entering clinical testing.

3 Semaglutide is currently in phase 3 clinical testing.

4 parental virus and merits consideration for clinical testing.

5 Some of these therapies have advanced to clinical testing.

6 but most CDK inhibitors have failed rigorous clinical testing.

7 pplements," which may not require additional clinical testing.

8 the same as vaccines entering Phase 1 human clinical testing.

9 bilization of such protein aggregates are in clinical testing.

10 strategy for SCLC treatment, which warrants clinical testing.

11 o minimize it will be important steps before clinical testing.

12 herapies and regimens are currently in (pre-)clinical testing.

13 re currently undergoing preclinical or early clinical testing.

14 should be taken forward for experimental or clinical testing.

15 latory drugs that are in the early stages of clinical testing.

16 coding regions of the genome (the exome) for clinical testing.

17 man mHAs in numbers and potency adequate for clinical testing.

18 atients with CKD are available and ready for clinical testing.

19 pproved in 2006 and 2009 following extensive clinical testing.

20 sion that can be gradually incorporated into clinical testing.

21 to prevent relapse are in various phases of clinical testing.

22 ll-molecule inhibitors are reported to be in clinical testing.

23 ersion from MCI to AD compared with baseline clinical testing.

24 clinical management of patients referred for clinical testing.

25 mising polymer-drug conjugate progressing to clinical testing.

26 th and metastasis, thereby supporting future clinical testing.

27 hies, and that EpoD could be a candidate for clinical testing.

28 slational approach including preclinical and clinical testing.

29 ographic atrophy in both pre and early-phase clinical testing.

30 muli that contained no monocular cues and on clinical testing.

31 a specific kinase inhibitor already in human clinical testing.

32 nt CLL patients would improve outcome merits clinical testing.

33 e activity that is in phase II and phase III clinical testing.

34 utcomes and may not optimally translate into clinical testing.

35 curation, model design, quality control, and clinical testing.

36 th neurodevelopmental disorders referred for clinical testing.

37 latory therapy tools available for immediate clinical testing.

38 ibitor compound, MP-10, has recently entered clinical testing.

39 bitors uncovered in this study are ready for clinical testing.

40 sults to frozen samples for multiple-analyte clinical testing.

41 g/kg every 3 months was selected for further clinical testing.

42 e bench into developmental programmes before clinical testing.

43 n-derived Abs promising candidates for human clinical testing.

44 rensic science and as well as toxicology and clinical testing.

45 es that block this integrin are currently in clinical testing.

46 e, and test interval are needed for reliable clinical testing.

47 " to support prioritization of compounds for clinical testing.

48 e tested in assays that are more amenable to clinical testing.

49 c treatment of cancer in humans and warrants clinical testing.

50 make this chemoimmunotherapy attractive for clinical testing.

51 approaches are undergoing further randomized clinical testing.

52 sently, at least two drugs are in late-stage clinical testing.

53 al-based emulsions are in advanced stages of clinical testing.

54 n of T. vaginalis PCR diagnosis into routine clinical testing.

55 eir efficacy against malaria awaits rigorous clinical testing.

56 otherapeutic strategy may be appropriate for clinical testing.

57 h inhibitory agents are currently undergoing clinical testing.

58 ese devices into the field for point-of-care clinical testing.

59 be addressed as these agents undergo further clinical testing.

60 easures by which they may be prioritized for clinical testing.

61 crotubule-targeting compounds are undergoing clinical testing.

62 argeted immunotherapies currently undergoing clinical testing.

63 te translation of experimental findings into clinical testing.

64 the laboratory on how to best adopt these in clinical testing.

65 i and BRD4i should be pursued in further pre-clinical testing.

66 inical model, establishing the rationale for clinical testing.

67 should have significant influence on future clinical testing.

68 e (Porcn) are candidate anticancer agents in clinical testing.

69 efficient repeat (TsolR13) was selected for clinical testing.

70 it convenient for patients to participate in clinical testing.

71 critical quality attributes appropriate for clinical testing.

72 re identified in research projects or during clinical testing.

73 , preclinical proof of concept, and possible clinical testing.

74 n functions were ascertained with imaging or clinical testing.

75 entially in analyzing patient samples during clinical testing.

76 ents for diarrhea were identified in routine clinical testing.

77 anufacture, as well as their preclinical and clinical testing.

78 tibody-drug conjugates are now in late-phase clinical testing.

79 genesis of cardiac arrest through systematic clinical testing.

80 esidual diagnostic specimens remaining after clinical testing.

81 nists are being carried forward into phase I clinical testing.

82 genome annotation, comparative genomics, and clinical testing.

83 ied viral pathogens in more samples than did clinical testing (30/90 versus 16/90; McNemar P = 0.001)

84 peutic effects in animal models and in early clinical testing ((90)Y-humanized PAM4 IgG, (90)Y-clivat

85 In clinical testing, Abs against PD-1 have resulted in psor

86 With further training and clinical testing across multiple sites, protocols, and i

87 vaccines have been developed and advanced in clinical testing, additional vaccine candidates may be n

88 At the point of care (POC), on-side clinical testing allows fast biomarkers determination ev

89 of predicting conversion to AD compared with clinical testing alone.

90 These results indicate that BEZ235 merits clinical testing, alone and in combination with other ag

91 e respiratory samples obtained after routine clinical testing and 27 matched liquid cultures).

92 ration of HER2-targeting agents brought into clinical testing and a renewed attempt to treat HER2-dri

93 cific antigen combinations for high-priority clinical testing and establishes a generalizable approac

94 n-1-amine, PF-4455242, which entered phase 1 clinical testing and has demonstrated target engagement

95 Although RTS,S has undergone extensive clinical testing and has progressed through phase III cl

96 decay engineering to design new formats for clinical testing and other fluorescence-based applicatio

97 cardiac arrest patients requires systematic clinical testing and regular follow-up to unmask the cau

98 Hence, there is a critical interplay between clinical testing and research leading to gene-disease as

99 Appropriate clinical testing and risk stratification are essential t

100 mportance of assessing a temporal window for clinical testing and thereby questioning the accuracy of

101 The development of biomarkers for clinical testing and validation can be facilitated by th

102 All had a myopathy by clinical evaluation, clinical testing, and biopsy.

103 s (JTT-705 and torcetrapib) are currently in clinical testing, and significantly raise high-density l

104 Several bnMAbs are currently in clinical testing, and we offer perspectives on their use

105 al mutant FLT3 inhibitors that is undergoing clinical testing, and which is currently in late-stage c

106 e leading dengue virus vaccine candidates in clinical testing are all based on live-virus vaccine pla

107 e current leading Zika vaccine candidates in clinical testing are based on live or killed virus platf

108 ghted and future directions for research and clinical testing are discussed.

109 tions of these results in vaccine design and clinical testing are discussed.

110 rtually all SARS-CoV-2 vaccines currently in clinical testing are stored in a refrigerated or frozen

111 he cell surface receptor cKit are undergoing clinical testing as a cell source for heart failure and

112 G and IC/anti-CTLA-4 should be developed for clinical testing as a potentially effective novel immuno

113 able immunostimulatory NCP promises to enter clinical testing as an immunotherapy against colorectal

114 arious stages of preclinical and early phase clinical testing as potential anticancer drugs.

115 the MDM2-p53 interaction have progressed to clinical testing as treatments for a variety of hematolo

116 anner, and the more potent bnMAbs will allow clinical testing at infusion doses that are practically

117 ents of T-tau and P-tau performed in routine clinical testing at the Clinical Neurochemistry Laborato

118 ntified 13 (22%) that were not identified by clinical testing at the source hospital.

119 cology failures reached expensive late-stage clinical testing before being abandoned.

120 Several other JAK2 inhibitors have entered clinical testing, but none have been approved and many h

121 rimarily related to lack of easily available clinical testing, but other factors included the presenc

122 In situations in which clinical testing cannot be performed or when uncertainty

123 A clinical testing cohort was used to gain a broader under

124 Under typical clinical testing conditions, increased forward scatter h

125 comparator tool combined with representative clinical testing could reduce the burden for completing

126 ective tool for verification of C. difficile clinical testing criteria and safe reduction of inflated

127 ighlight the importance of using appropriate clinical testing criteria.

128 ent de novo events were further evaluated in clinical-testing data from Children's Hospital Boston an

129 We assessed clinical testing dates, approved indications, and regula

130 Clinical testing detects a fraction of carbapenem-resist

131 Despite its prevalence, clinical testing does not yield a cell or molecular base

132 r locations designed to match those found in clinical testing environments.

133 Unexpected drug activities discovered during clinical testing establish the need for better character

134 oriatic arthritis, and related agents are in clinical testing for a variety of inflammatory disorders

135 tumorigenesis, and Notch antagonists are in clinical testing for application in cancer.

136 Clinical testing for BMPR2 mutations is available and ma

137 ardial infarction and are undergoing further clinical testing for cardiomyopathy.

138 potent CCR5 coreceptor antagonist that is in clinical testing for daily oral pre-exposure prophylaxis

139 re more likely than cardiac GCs to recommend clinical testing for family members even though testing

140 ults with cirrhosis, suggesting that further clinical testing for HE is warranted.

141 reatments that are undergoing preclinical or clinical testing for hypertension treatment.

142 rationale for extending HDAC inhibitors into clinical testing for indications involving these organs.

143 ation approaches likely to move forward into clinical testing for lymphomas.

144 notherapies currently in worldwide phase III clinical testing for melanoma are discussed.

145 As clinical testing for Mendelian causes of colorectal canc

146 receptor (EGFR)-targeted therapies, limited clinical testing for RAS pathway mutations has recently

147 A antibodies; such a therapy is currently in clinical testing for spinal cord injury.

148 I-A, is the only one to have been subject to clinical testing for the treatment of metastatic tumours

149 the recombinant CDR2 protein used in routine clinical testing for these antibodies.

150 half-life, are also important factors in the clinical testing for this virus.

151 irectly compared eight drugs, approved or in clinical testing, for the ability to block entry mediate

152 targeting this protein that are amenable for clinical testing has been challenging.

153 Pre-clinical testing has contributed to the recent approval

154 Early prototype development and clinical testing have shown that a consumer digital came

155 Successes in randomized clinical testing have supported the growing appreciation

156 less likely to fail in the various stages of clinical testing, have fewer postapproval withdrawals, a

157 liable predictors of hepatic toxicity in non-clinical testing; however, mice are considered to be a s

158 l biases are generally not considered during clinical testing; however, we suggest that such biases m

159 tide (DEP), is currently undergoing phase II clinical testing in a variety of malignancies.

160 with unusual cytotoxic properties that is in clinical testing in cancer.

161 se (FAK) inhibitors are currently undergoing clinical testing in combination with anti-PD-1 immune ch

162 Phase II clinical testing in ERBB2 exon 20-mutant non-small cell

163 ent sensitivity and specificity suitable for clinical testing in high-risk populations.

164 The results warrant further clinical testing in larger trials.

165 t CDK inhibitor currently undergoing phase-2 clinical testing in lung and B-cell malignancies.

166 and generates proof-of-concept for ARGX-111 clinical testing in MET-positive oncologic malignancies.

167 inical models provided the framework for its clinical testing in MM, which has already provided favor

168 he need to improve the efficiency of phase 2 clinical testing in neuro-oncology to expeditiously tran

169 erated c-Met inhibitor, currently in Phase 3 clinical testing in non-small cell lung cancer patients.

170 ompound M8891, which is currently in phase I clinical testing in oncology patients.

171 reating metastatic TNBC and warrants further clinical testing in patients.

172 very, early drug development, and definitive clinical testing in pivotal trials.

173 findings offer a rational strategy to guide clinical testing in preidentified subsets of patients wh

174 This opens the possibility of clinical testing in rheumatic diseases of childhood.

175 stigational compound is currently in phase 1 clinical testing in subjects with hemophilia A or B.

176 to replace conventional long and costly pre-clinical testing in the new drug administration process.

177 ly focused approaches for gene discovery and clinical testing in the next few years.

178 een substantiated with their development and clinical testing in the treatment of cancer.

179 -inducing potential are currently undergoing clinical testing in transplantation, autoimmune diseases

180 re currently under intensive development and clinical testing) in individuals with DN and perhaps oth

181 t diagnostic assays that may be suitable for clinical testing, in field and laboratory settings.

182 Few tau-directed drugs are presently in clinical testing, in part because of the difficulty in i

183 into the assay process during the period of clinical testing included software enhancements, improve

184 Clinical testing included visual acuity, visual fields,

185 scue was evaluated using non-invasive, human clinical testing, including fundus auto-fluorescence, op

186 al, a variety of anti-HIV genes have reached clinical testing, including gene-editing enzymes, protei

187 and currently at least 33 different drugs in clinical testing--including several in pivotal trials--c

188 hysiological salt concentration, relevant to clinical testing, infectivity and, therefore, oncolytic

189 S identified all viruses detected by routine clinical testing (influenza A [n = 3], human metapneumov

190 (bsAbs) on a large scale for preclinical and clinical testing is a challenging task.

191 r clinical-grade immune cell processing, its clinical testing is feasible and warranted.

192 ever received a BRAF inhibitor; confirmatory clinical testing is ongoing.

193 g MRR based malaria diagnostics suitable for clinical testing is the fact that MRR baseline fluctuati

194 However, in clinical testing, it has shown limited benefit in patien

195 Interpretations are submitted by clinical testing laboratories, research laboratories, lo

196 method can be applied immediately in current clinical testing laboratories.

197 ques, and extensive bench, pre-clinical, and clinical testing, lead failure (LF) remains the Achilles

198 ion discrepancies between patient report and clinical testing may be owing to home lighting may initi

199 modulators or cysteamine, justifying further clinical testing of (R)-roscovitine or optimized derivat

200 of mutations in this disease, the results of clinical testing of 699 advanced melanoma patients using

201 Here, we demonstrated the development and clinical testing of a disposable, multiplexed sensing de

202 Clinical testing of a human IgG1 anti-CD27 Ab, varliluma

203 we demonstrate the technical development and clinical testing of a novel electronics enabled microflu

204 ility genes at once, suggesting that routine clinical testing of all incidence cases should be consid

205 th melanoma providing a strong rationale for clinical testing of alternative dosing regimens.

206 Results provide a rationale for broader clinical testing of AT1R-targeted molecular imaging.

207 to the identification, characterization, and clinical testing of ataluren, a new therapeutic with the

208 normal caspase-1 activation, and support the clinical testing of caspase-1 inhibitors such as VX-765

209 This study suggests that clinical testing of celecoxib as a preventive for hepati

210 Clinical testing of CEP-701 as a novel molecularly targe

211 tion and presents a strong rationale for the clinical testing of combination MEK and PI3K targeted th

212 efficacious in these models, indicating that clinical testing of combinations of BCR-ABL kinase inhib

213 Our findings strongly support the clinical testing of combined hormone antagonist-low-leve

214 Further clinical testing of DENVax in different age groups and i

215 We initiated clinical testing of engineered T cells expressing an aff

216 provide rationale and practical platform for clinical testing of expanded and activated NK cells for

217 Rn in human biology, including insights that clinical testing of FcRn inhibitors have provided into F

218 Clinical testing of FLT3 inhibitors as molecularly targe

219 acute lymphoblastic leukemia (T-ALL) led to clinical testing of gamma-secretase inhibitors (GSIs) th

220 To allow for the clinical testing of human CMV (HCMV)-based vaccines we c

221 hese results provide compelling evidence for clinical testing of IMiDs alone and in combination with

222 uced at higher temperatures enabling on-site clinical testing of infectious agents.

223 Phase I clinical testing of inhibition of Janus kinase 2, active

224 tial as a non-human animal model for the pre-clinical testing of iNKT-stimulating glycolipids.

225 enhanced activity and to support the future clinical testing of intratumoral administration of immun

226 hat we provide should help with research and clinical testing of knee-ankle prostheses in real-world

227 In summary, our results support the clinical testing of lymphodepletion and PD-1/PD-L1 block

228 These results warrant further clinical testing of META060 for its therapeutic potentia

229 tients with acute diarrhea have included the clinical testing of modifications to the standard oral r

230 he feasibility for using challenge models in clinical testing of new disease intervention strategies.

231 Pharmaceutical research requires pre-clinical testing of new therapeutics using both in-vitro

232 design, and a mechanistic rationale for the clinical testing of nonviral miRNA mimetics.

233 with conventional screening and monotherapy clinical testing of novel agents.

234 ertaken into the development and preliminary clinical testing of novel technologies including robotic

235 It set the stage for clinical testing of novel therapeutic strategies, such a

236 ce and risk, consideration might be given to clinical testing of PALB2 by complete genomic sequencing

237 These experiments support the clinical testing of pDNA vaccine candidates that may ult

238 e findings may support the rationale for the clinical testing of peripherally restricted CB1R antagon

239 Our findings support the clinical testing of PKC412 for treatment of mutant PDGFR

240 nt method for high-content screening and pre-clinical testing of potential STAT3 inhibitors in live c

241 ity of PR-171 and provide validation for the clinical testing of PR-171 in the treatment of hematolog

242 These include further development and clinical testing of predictive risk scores and assays; g

243 This assay/system performed well in clinical testing of regular seasonal influenza virus sub

244 This study establishes a foundation for clinical testing of sequential fractionated radiation fo

245 d in this study provides a rationale for the clinical testing of SGN-40 in the treatment of CD40+ B-l

246 ation and provide a strong rationale for the clinical testing of TGF-beta signaling blockade to enhan

247 Based on these findings, clinical testing of the BIBW2992/rapamycin combination i

248 o and in vitro This study further encourages clinical testing of the conserved mosaic T-cell vaccine

249 based on laboratory hypotheses, but without clinical testing of the hypotheses to show utility for t

250 rant further development and preclinical and clinical testing of the next generation of candidate MAP

251 provide a strong rationale for extending the clinical testing of the novel antimyeloma agent I-BET762

252 e present work describes the development and clinical testing of the paper-based biosensor that measu

253 pathomechanisms of recessive RYR1 RM and pre-clinical testing of therapies for efficacy.

254 pments lie mostly in the lessons learnt from clinical testing of these approaches.

255 These results therefore support clinical testing of this noninvasive-targeted drug deliv

256 CD33-directed antitumor activity and support clinical testing of this novel therapeutic in patients w

257 Further optimization and clinical testing of this promising approach are indicate

258 regulators and provides a rational basis for clinical testing of this therapeutic approach.

259 uses and temozolomide, and should propel the clinical testing of this therapy approach in patients wi

260 These studies form the basis for further clinical testing of TORC1/2 inhibitors in MM.

261 otential of more pragmatic approaches to the clinical testing of vaccine candidates, the field has pr

262 targeting of CSC prompts a new paradigm for clinical testing of VS-5584: clinical trials designed wi

263 ection of our data set with genes on cardiac clinical testing panels and the druggable genome reveals

264 arrying a SPRED1 mutation identified through clinical testing participated with their families in a g

265 er of drug candidates and accelerate the pre-clinical testing process subject to animal testing upon

266 stimation of CA activity in erythrocytes for clinical testing purposes.

267 ism that will have enormous applications for clinical testing purposes.

268 -2-family mRNAs or proteins are currently in clinical testing, raising hopes that a new class of anti

269 -2 family mRNAs or proteins are currently in clinical testing, raising hopes that a new class of anti

270 Clinical testing reliability was compared between expert

271 iants in genes associated with CPVT from WES clinical testing represent disease-associated biomarkers

272 However, clinical testing revealed a high incidence of duplicatio

273 tion of 120 sequential samples submitted for clinical testing revealed a variety of silent and amino

274 ned from finger prick (Theranos) and 2 major clinical testing services that require standard venipunc

275 Clinical testing showed 95% sensitivity for influenza A

276 ith at least one DNA virus detected in prior clinical testing showed a total percent agreement of mNG

277 Results from transgenic mice and extensive clinical testing support the hypothesis that biallelic B

278 roval paradigm comprising discrete phases of clinical testing that culminate in a large randomized su

279 as testified by the number of candidates in clinical testing that unselectively target both PARP-1 a

280 elf, experimental medicine, and larger-scale clinical testing-there are specific needs for academic p

281 Because DOTATOC has undergone extensive clinical testing, this human reporter system has the pot

282 ugh ethyl pyruvate has undergone early-phase clinical testing, this was done without consideration of

283 Their limited use in clinical testing though has resulted largely from uncert

284 17, but total time from the authorization of clinical testing to approval has remained at approximate

285 ure for lymph node metastasis indicates that clinical testing to assess risk for lymph node metastasi

286 development strategies and outcomes of their clinical testing to date.

287 rate reactions in the same assay for routine clinical testing to detect influenza A and B viruses and

288 ROS and MAP) or biennial (ACT) cognitive and clinical testing to identify incident cases of dementia

289 man study groups and is now undergoing wider clinical testing to secure FDA approval for general use.

290 compounds transition from discovery, through clinical testing, to drugs.

291 en resistance in prostate cancer amenable to clinical testing using available targeted therapies.

292 mising malaria vaccine candidate for further clinical testing using more-potent adjuvant formulations

293 positive negative controls in HP and CAP/CTM clinical testing was <0.5% over 6 to 7 months of testing

294 nce of weekly home monitoring over 6-monthly clinical testing was retained even when home monitoring

295 tatic uveal melanoma did not warrant further clinical testing when assessed by ORR, although minor tu

296 models, extended safety studies and further clinical testing will be required before the full therap

297 ines are human topoisomerase I inhibitors in clinical testing with improved physicochemical and biolo

298 ible loss of visual function in LHON support clinical testing with mutated G11778A mitochondrial DNA

299 ate the advancement of promising projects to clinical testing with the contributions of multidiscipli

300 32765) is the most advanced BTK inhibitor in clinical testing, with ongoing phase III clinical trials